GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
2.730 USD   +10.98%
07/05Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 3000 Value Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 2500 Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

HC Wainwright Adjusts Gritstone Bio's Price Target to $15 From $24, Maintains Buy Rating

03/14/2022 | 08:43am EDT


© MT Newswires 2022
All news about GRITSTONE BIO, INC.
07/05Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 3000 Value Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 2500 Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell Small Cap Comp Value Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 2000 Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 2000 Value Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 2000 Dynamic Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 3000E Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell 3000 Index
CI
06/24GRITSTONE BIO, INC.(NASDAQGS : GRTS) dropped from Russell Small Cap Completeness Index
CI
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 16,8 M - -
Net income 2022 -125 M - -
Net cash 2022 2,29 M - -
P/E ratio 2022 -1,71x
Yield 2022 -
Capitalization 199 M 199 M -
EV / Sales 2022 11,7x
EV / Sales 2023 -3,81x
Nbr of Employees 201
Free-Float 97,0%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,73 $
Average target price 11,33 $
Spread / Average Target 315%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
Erin E. Jones Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-78.77%199
CSL LIMITED-5.48%90 967
WUXI BIOLOGICS (CAYMAN) INC.-16.21%44 412
SAMSUNG BIOLOGICS CO.,LTD.-10.85%43 617
BIOGEN INC.-11.40%31 133
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-3.75%28 559